All In Biotech

Drug Trial Radar · NCT03918278

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

222

Actual

Start

Jun 19, 2019

Primary completion

Jun 9, 2025

Study completion Jun 9, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors for which there is no available therapy which may convey clinical benefit. Part 2 is expansion cohort to determine safety and tolerability of MK-0482 in combination with pembrolizumab with and without chemotherapy in participants with advanced tumor specific cohorts.

Conditions

  • Neoplasms

Interventions

  • MK-0482Biological

    IV infusion

  • pembrolizumabBiological

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • Nab-paclitaxelDrug

    IV infusion

  • GemcitabineDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • PemetrexedDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Part 1 only)Time frame: Cycle 1 (Up to 21 days)
  2. Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 27 months
  3. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 24 months
  4. Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Part 2 only)Time frame: Up to approximately 28 days from the start of study intervention

Locations

16 sites in 8 countries. Site status is shown where the registry gives one.

  • Henry Ford Health System ( Site 0002)

    Detroit, Michigan

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0003)

    Hackensack, New Jersey

  • Next Oncology ( Site 0001)

    San Antonio, Texas

  • Macquarie University ( Site 0033)

    Macquarie University, New South Wales, Australia

  • Alfred Health ( Site 0031)

    Melbourne, Victoria, Australia

  • BC Cancer - Vancouver Center ( Site 0010)

    Vancouver, British Columbia, Canada

  • Princess Margaret Cancer Centre ( Site 0011)

    Toronto, Ontario, Canada

  • FALP-UIDO ( Site 0100)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 0101)

    Santiago, Region M. de Santiago, Chile

  • Hadassa Ein Karem Medical Center ( Site 0022)

    Jerusalem, Israel

  • Chaim Sheba Medical Center ( Site 0020)

    Ramat Gan, Israel

  • Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (

    Milan, Italy

  • ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 0091)

    Siena, Tuscany, Italy

  • Seoul National University Hospital ( Site 0061)

    Seoul, South Korea

  • Asan Medical Center ( Site 0060)

    Seoul, South Korea

  • Hospital Clinic i Provincial ( Site 0041)

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.